Navigation Links
Halt Medical Presents Strong Results of International Fibroid Studies at National Institutes of Health Global Congress
Date:12/20/2010

BETHESDA, Md., Dec. 20, 2010 /PRNewswire/ -- Women suffering from uterine fibroids, a debilitating condition that affects more than seven million women in the U.S., may soon have reason for hope.  Halt Medical, a biomedical company based in the San Francisco Bay Area, is developing a minimally invasive procedure for treating the condition. The company recently presented their findings from studies in Latin America at the NIH Global Fibroid Congress.  

"Uterine fibroids are the leading cause of women's surgeries worldwide," says Russ DeLonzor, President and Chief Operating Officer of Halt.  "Currently women must choose between suffering with their symptoms or sacrificing their uterus." The symptoms can be severe, ranging from acute pelvic pain, urinary incontinence, and painful intercourse, to excessive menstrual bleeding.

"Hysterectomy surgeries can be highly traumatic for women," says DeLonzor. "It's not only an emotional decision, but also a painful one, with a typical six-week recovery time. Halt Medical was formed with a single goal in mind," adds DeLonzor, "to give women suffering with the awful symptoms caused by fibroids an alternative to losing their uterus."

The Halt Fibroid System is a precise, minimally invasive outpatient procedure that allows women to return to normal activities in just 3 – 4 days.  A slender probe is inserted into the fibroid under ultrasound guidance. Once in position, the system delivers a specified amount of energy to the fibroid.  The heat generated in the process destroys the fibroid, relieving the symptoms while sparing the uterus.     

"We commend the NIH for sponsoring this forum," DeLonzor says. "Uterine fibroids are a significant public health issue, and we are honored to share the results of our Latin American Studies."  

The results of Halt's international studies have led to recent approvals for treating uterine fibroids in Canada and the European Union.  The Halt System may be used for general surgical use in the US, however it is currently cleared by the FDA only for investigational use for treating symptomatic fibroids.  

Information about the Halt Fibroid Study and a list of clinical sites in the US may be found at www.clinicaltrials.gov, study number NCT00874029.


'/>"/>
SOURCE Halt Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
2. Inverness Medical Innovations Features Innovative TB Diagnostic - Clearview(R) TB ELISA at AIDS 2008
3. ICON Medical Imaging Launches New Service to Boost Reliability of Cardiology Studies
4. Informed Medical Communications Highlights Opportunity in Revised PhRMA Code
5. Concentric Medical(R) Announces Co-Marketing Agreement With InTouch Health(R) to Advance Acute Ischemic Stroke Care
6. BioMS Medical Announces Second Quarter 2008 Results
7. ATS Medical to Participate at the Fourth Annual Noble Financial Equity Conference
8. Mentice, Inc. and the Milwaukee Area Technical College (MATC) Announce Their Partnership in the Area of Procedural Medical Simulation
9. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
10. Bluestar Silicones Presents Adhesive Gels for Wound Care at Medical Grade Polymers Conference
11. China Sky One Medical, Inc. Develops Nasal Spray for Rheumatic Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... Ken Hanson, a medical imaging research scientist ... have been selected as this year’s recipients of two top awards from SPIE, ... along with other honorees to accept their awards at a banquet in San Diego, ...
(Date:6/22/2017)... ... June 21, 2017 , ... Beaker, the industry’s ... in the life sciences industry, today announces a strategic partnership with Alcami Corporation, ... full advantage of Beaker’s expertise in executive recruitment solutions, providing Alcami with access ...
(Date:6/22/2017)... Germany (PRWEB) , ... June 22, 2017 , ... ... is taking over the allergy specialists DST Diagnostische Systeme & Technologien GmbH, thereby ... all know someone who suffers from hay fever, urticaria, asthma, atopic eczema or ...
(Date:6/22/2017)... ... June 22, 2017 , ... Tunnell ... the biopharma and life sciences industries, continue to be in demand for their ... Wolf will be speaking on “The State of Information Governance in the Biopharmaceutical ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, ... secure authentication solutions, today announced that it has ... Advanced Research Projects Activity (IARPA) to develop next-generation ... program. "Innovation has been a driving ... Thor program will allow us to innovate and ...
(Date:4/11/2017)... , April 11, 2017 No ... but researchers at the New York University Tandon ... of Engineering have found that partial similarities between ... systems used in mobile phones and other electronic ... The vulnerability lies in the fact ...
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
Breaking Biology News(10 mins):